Multiparameter immunoprofiling for the diagnosis and differentiation of progressive versus nonprogressive nontuberculous mycobacterial lung disease-A pilot study.

Clinical prediction of nontuberculous mycobacteria lung disease (NTM-LD) progression remains challenging. We aimed to evaluate antigen-specific immunoprofiling utilizing flow cytometry (FC) of activation-induced markers (AIM) and IFN-γ enzyme-linked immune absorbent spot assay (ELISpot) accurately identifies patients with NTM-LD, and differentiate those with progressive from nonprogressive NTM-LD. A Prospective, single-center, and laboratory technician-blinded pilot study was conducted to evaluate the FC and ELISpot based immunoprofiling in patients with NTM-LD (n = 18) and controls (n = 22).

New diagnostics for the spectrum of asymptomatic TB: from infection to subclinical disease.

TB remains a leading cause of morbidity and mortality worldwide. However, most infected immunocompetent individuals are asymptomatic and only 5-10% of these will eventually develop active TB during their lifetime (typically within 2 years after exposure). Therefore, rapid diagnosis and efficient management of asymptomatic infected individuals who are at the highest risk of progression and transmission remain major clinical and public health challenges.

Malignant fibroma presenting as a hypoglycemia and coma in a 45-year-old male patient: A case report.

Solitary fibrous tumors (SFTs) are a rare group of spindle cell neoplasm of submesothelial origin with malignant potential and can present as hypoglycemia secondary to excess secretion of insulin-like growth factor II (IGF-II) from the tumor. Early diagnosis and treatment are very important in such cases to prevent hypoxic injury to the brain secondary to hypoglycemia. Here, we are presenting a case of a 45-year-old male patient, who presented with recurrent episodes of hypoglycemia spells, and later on, it was diagnosed that hypoglycemic spells were secondary to fibroma.